We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00121849
First Posted: July 21, 2005
Last Update Posted: May 5, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Bill and Melinda Gates Foundation
Information provided by:
IDRI
  Purpose
This study will evaluate the safety of the Leish-111f + MPL-SE vaccine in adult subjects with a previous exposure to the Leishmania parasite (but without current or past history of leishmaniasis).

Condition Intervention Phase
Cutaneous Leishmaniasis Biological: Leish-111f + MPL-SE vaccine Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Leish-111f + MPL-SE Vaccine in Montenegro Skin Test-Positive Healthy Adults

Resource links provided by NLM:


Further study details as provided by IDRI:

Primary Outcome Measures:
  • Adverse events
  • Dose-limiting toxicities: hematology and serum chemistries at Screening and Days 7, 35, 63, and 84

Secondary Outcome Measures:
  • IgG and T-cell responses to the Leish-111f protein: immunological evaluations at Days 0, 84, and 168
  • Skin test reactivity to the Leish-111f protein at Days 0, 84, and 168

Estimated Enrollment: 12
Study Start Date: August 2005
Estimated Study Completion Date: February 2006
Detailed Description:
Cutaneous leishmaniasis is a disfiguring disease that can progress to mucosal leishmaniasis, a more serious and possibly fatal form of Leishmania disease. All available medical therapies require weeks of treatment and cause significant toxicity. It appears that Leishmania infections can be eliminated or prevented by T helper 1 immune responses. These findings argue that a vaccine that generates a T helper 1 response against the parasite will prevent the infection and disease. This is a phase 1, open-label study to evaluate the safety, tolerability and immunogenicity in Montenegro skin test (MST)-positive healthy adults of an investigational vaccine being developed for the prophylaxis of cutaneous leishmaniasis. The vaccine, identified as Leish-111f + MPL-SE, consists of a recombinant three-antigen Leishmania polyprotein (Leish-111f, 10 μg) together with the adjuvant MPL-SE (25 μg). The vaccine will be given to each study subject three times at 4 week intervals.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Must have positive Montenegro skin test (reaction >5 mm)
  • Must be in good general health with normal lab values
  • Negative for HIV, hepatitis B and C

Exclusion Criteria:

  • History of leishmaniasis or exposure to Leishmania vaccine or MPL-SE.
  • Pregnant or nursing female
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00121849


Locations
Colombia
Programa de Estudio y Control de Enfermedades Tropicales (PECET)
Medellín, Colombia
Sponsors and Collaborators
IDRI
Bill and Melinda Gates Foundation
Investigators
Principal Investigator: Iván D Vélez Bernal, MD, PhD PECET, Medellin, Colombia
  More Information

ClinicalTrials.gov Identifier: NCT00121849     History of Changes
Other Study ID Numbers: IDRI-LCVPX-105
First Submitted: July 15, 2005
First Posted: July 21, 2005
Last Update Posted: May 5, 2006
Last Verified: May 2006

Keywords provided by IDRI:
Leishmaniasis,
Subunit Vaccine,
Prevention,
T cell

Additional relevant MeSH terms:
Leishmaniasis
Leishmaniasis, Cutaneous
Euglenozoa Infections
Protozoan Infections
Parasitic Diseases
Skin Diseases, Parasitic
Skin Diseases, Infectious
Skin Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs